Biotech's strengths: Innovation and product launches

David Pinniger, Lead Manager of the Polar Capital Biotechnology Fund, explains why he believes the fundamentals that drove strong performance in 2025 remain intact. He argues that new product launches, positive clinical data, and continued M&A activity could re-engage investors and serve as catalysts for the sector. With the team’s focus on later-stage and commercial-stage biotech companies, he believes the Fund is well positioned for the next phase of biotech growth.